Theravance Biopharma (TBPH) Misses Q2 EPS by 10c

Theravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of ($0.11), $0.10 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $11.1 million versus the consensus estimate of $12.5 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
• Innovex closes $95M acquisition of TCO Group AS